CN102309761A - Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof - Google Patents
Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof Download PDFInfo
- Publication number
- CN102309761A CN102309761A CN 201010213696 CN201010213696A CN102309761A CN 102309761 A CN102309761 A CN 102309761A CN 201010213696 CN201010213696 CN 201010213696 CN 201010213696 A CN201010213696 A CN 201010213696A CN 102309761 A CN102309761 A CN 102309761A
- Authority
- CN
- China
- Prior art keywords
- solution
- chitosan
- dca
- bile acid
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an uncharged amphiphilic chitosan nano drug carrier and a preparation method and application thereof. The preparation method is characterized in that lipophilic micromolecular deoxidized bile acid and hydrophilic micromolecular glycide are respectively grafted on chitosan molecules, thus obtaining a degradable amphiphilic chitosan material with good biocompatibility; in a wide pH solution, the amphiphilic chitosan material can quickly form a nano micelle which has a grain size of 150-300nm and is uniformly distributed through the principle of molecular self assembly under ultrasound conditions; and the inner lipophilic structure of the nano micelle is beneficial to improvement of the solubility of fat-soluble drugs in the aqueous solution, thus being expected to improve the in-vivo bioavailability of the drugs. The method has the advantages of simple requirements for instruments and equipment, simple and controllable preparation process and easy realization of large scale, so that the method is suitable for preparing nano carrier release systems of antitumor drugs with high price and poor water solubility and bioavailability such as paclitaxel, doxorubicin, camptothecin, vincaleucoblastine and the like. As a new dosage form of the antitumor drugs, the drug carrier has wide market prospects and potential clinical tumor treatment values.
Description
Technical field
The present invention relates to the preparation of lipophilic medicament nano-carrier and the loading of medicine, specifically is a kind ofly to combine dialysis to prepare surface hydrophilic, inner lipophilic nano-particle through the molecule self assembly and the oiliness antitumor drug is loaded into the method in the inner oleophylic nuclear at ultrasound condition.
Background technology
The hydrophilic amphipathy macromolecule of forming with lipophilic segments forms nano-micelle through molecule self assembly principle in aqueous solution.Because this micellar surface is hydrophilic; Inner oleophylic, therefore this micelle carries with the controlled release field at medicine and has a lot of advantages, as; Improve the dissolubility of lipophilic medicament in solution, avoid being prone to the degraded medicine and in not reaching the process of action target spot, degrade, improve in vivo circulation time of bioavailability of medicament, prolong drug, improve medicine distribution in vivo; Simultaneously can also be through micellar surface is simply modified, make its targeting get into disease cell and reduce medicine in use to side effect (Science, 2004 of normal structure; 303,1818-1822).Therefore, in the past several years, utilize the nano-micelle of amphipathy macromolecule preparation to be considered to a kind of very promising carrier that is applied to bioactive molecules transportations such as fat-soluble medicine, polypeptide, protein, DNA and controlled release.Consider cost, the easy controllability of operation and preparation and the clinical practice factors such as biocompatibility in use of amphipathy macromolecule in the preparation process; In recent years; Increasing research trend is biodegradable in utilizing natural biomaterial (like polysaccharide) to prepare, amphipathy macromolecule polymer (Bioconjugate chemistry, the 10.1021/bc070052e of good biocompatibility; Biomacromolecules, 10.1021/bm7009587).
The polysaccharide that chitosan is made up of glucosamine and acetylglucosamine, it has characteristics such as better biocompatibility, biodegradable and toxicity be low, has been widely used as tissue engineering bracket, wound dressing, hemostatic material etc.Simultaneously owing to have a large amount of amino in its strand; And the character of positively charged under certain conditions has been applied to research (Chemical Review, 2004 of biopharmaceutical macromolecular drug carriers such as polypeptide, albumen property, DNA and RNA; 104,6017-6084).Same because a large amount of amino existence in the chitosan chain; Chitosan is carried out chemical modification seem particularly easy; Thereby so can on the chitosan chain, form amphiphilic chitosan derivative by grafting lipophile micromolecule, and in aqueous solution, prepare nano-micelle through molecule self assembly principle.At present; Preparation amphipathic chitose macromolecule mainly concentrates on following two kinds of methods; The one, directly utilize the fatty acid of C8-C22 or the carboxyl on the carboxylated product of aliphatic alcohol, carry out amidation process grafting lipophile micromolecule (Chinese patent: CN1883708) with amino on the chitosan; Thereby a kind of in addition method be utilize C8-C22 halogenated alkane or C8-C22 the aldehyde molecule respectively with chitosan on amino carry out nucleophilic displacement of fluorine or schiff base reaction and reduction and reach the (Chinese patent: CN1839805) of the aminoalkylization on the chitosan.More than two kinds of methods, the former the operation simpler.But patent (Chinese patent: only be confined to CN1883708): the fatty acid that at molecular weight is grafting C8-C22 on the chitosan chain of 1.5-51KDa.The low-molecular weight chitoglycan degraded is very fast, and the pharmaceutical carrier of preparation exists the prominent phenomenon of releasing of medicine, is unfavorable for testing the controlled release of medicine long period.Because the fatty acid of using in its patent is flexible straight chain; Polymer micelle is poor through the dilution rear stability; Therefore in order to improve its stability; Need carry out surface chemical modification by the micromolecule with bi-functional on the nano-micelle surface, build bridge through the intermolecular chemical bond on polymeric micellar surface, to improve the stability of polymeric micellar.And; Existing research shows; Because chitosan itself need could dissolve under acid (pH＜6.5) condition; And the pH value of blood is neutral under people's the physiological condition, and therefore an amphipathic drug carrier material that pull bar lipophile micromolecule prepares is used owing to precipitating under the neutrallty condition to be difficult in clinically on chitosan.The present invention attempts to adopt more fatty acid of a kind of carbon number and chitosan (15KDa-100KDa) to form amphiphilic chitosan derivative through amidation process; Little minute (+)-2,3-Epoxy-1-propanol of grafting quaternary amine type hydrophilic on this amphiphilic chitosan derivative subsequently; Thereby preparation possesses the easy amphiphilic chitosan derivative that dissolves under the extensive pH value, and uses lipophile anti-tumor small molecular paclitaxel to investigate its loading and release as model drug through ultrasonic dialysis.The deoxidation bile acid is a kind of important C24 bile acid chemical compound that itself just exists in the body, and it possesses nontoxic, good biocompatibility and characteristics such as biodegradable.And the fatty acid that it is made up of several rings with rigid structure; Therefore for the fatty acid of the flexible chain C8-C22 of routine; When on the chitosan chain, identical percent grafting being arranged, the nano-micelle of formation is more stable, has just avoided with the micromolecule of bi-functional the chitosan nano micellar surface having been carried out further chemical modification certainly; And grafting hydrophilic small molecules has on this basis improved the water solublity of amphiphilic chitosan derivative; Thereby increased different molecular weight Application of Chitosan scope greatly, preparation technology becomes simple easy operating and suitability for industrialized production simultaneously.So the present invention adopts the deoxidation bile acid, chitosan and the grafting of dehydration glyceryl trimethyl ammonium chloride prepare a kind of good biocompatibility, biodegradable, stable nano-medicament carrier loads lipophile anti-tumor small molecular paclitaxel, and investigate its release.The result means that this material has vast market prospect and potential clinical therapy of tumor is worth.
Summary of the invention
The present invention provides a kind of not charged amphiphilic chitosan nanometer pharmaceutical carrier and preparation and application; It is a kind of novel amphiphilic chitosan derivative; This material is under ultrasound condition; Through molecule self assembly principle, can form the chitosan nano micelle fast and load the antitumor drug paclitaxel with this micelle.
For realizing above-mentioned purpose, the preparation scheme that the present invention adopts is:
A kind of not charged amphiphilic chitosan nanometer pharmaceutical carrier; Its successively by deoxidation bile acid and (+)-2,3-Epoxy-1-propanol respectively the glucosamine in the chitosan carry out amidation process and thereby electrophilic addition reaction prepares the chitosan derivatives by the amphipathic positively charged of good water solubility of N-[(2,3)-dihydroxypropyl] glucosamine, deoxidation bile acid amides glucosamine, acetylglucosamine and glucosamine composition.
Said preparation of drug carriers method; Under the catalytic action of catalyst EDC and NHS; Hydrophilic macromolecule chitosan (Mw15KDa-100KDa) and lipophile micromolecule deoxidation bile acid with good biocompatibility pass through amidation process, thereby form good biocompatibility, degradable amphiphilic chitosan derivative CS-DCA.Through on the basis of CS-DCA, carrying out a step, form quaternary amine shape amphiphilic chitosan derivative through electrophilic reaction grafting quaternary amine shape micromolecule (+)-2,3-Epoxy-1-propanol (Glycidol).In wide pH value solution, utilize the principle of molecule self assembly, the nano-micelle that under ultrasound condition, prepares particle diameter 150-350nm and be evenly distributed.Because this micelle is special to be surface hydrophilic, inner oleophylic, can realize that therefore the embedding of lipophilic medicament such as paclitaxel is loaded, form the Nano medication delivery system.
Specific operation process is following:
1) under the room temperature, the 1-4g chitosan is dissolved in the 50-200mL aqueous hydrochloric acid solution, the NaOH with 1-10N adjusts to 5.0-6.0 with pH value of solution subsequently, forms the chitosan solution of transparent 1-2% (w/v).
2) get a certain amount of deoxidation bile acid; The ratio of the amount of glucosamine residue is 0.10-0.30 in the amount that makes the deoxidation bile acid and the chitosan; It is joined in the DMSO solution of 50-100mL; The EDC and the NHS that amount such as in deoxidation bile acid solution, add subsequently, and keep EDC constant in 1.0 with the ratio of the amount of deoxidation bile acid: 1-1.5: 1.Deoxidation bile acid, EDC and NHS are at room temperature in 500-1500rpm reaction 30-60min.
3) mixed solution that deoxidation bile acid, EDC and NHS is reacted 30-60min in DMSO slowly is added drop-wise in 30-60min in the chitosan solution, under the mixing speed of 500-1500rpm, reacts 18-36h.
4) above-mentioned reaction mixture is joined in the 200-500mL methanol, and with NaOH solution pH value is adjusted to neutrality and makes chitosan graft product deposition.Centrifugal collecting precipitation subsequently.
5) above-mentioned deposition is dissolved in the aqueous solution of 50-200mL acidity (pH1-5) again, and in the repetitive operation step 4) 3-5 time, but for the last time methanol being changed to ethanol gets final product.Thereby the white gels product vacuum drying under room temperature that obtains is prepared CS-DCA.
6) above-mentioned product C S-DCA is got that 0.5-4g joins in the 25-200mL aqueous solution (0.25-2.0mL acetic acid) and be stirred to fully in 500-1500rpm and be mixed; Subsequently above-mentioned mixed liquor is heated to 40-60 ℃; And to wherein dripping a certain amount of (+)-2,3-Epoxy-1-propanol (Glycidol), reaction 18-36h; And the proportion control of the amount of substance of glucosamine is 3: 1 to 6: 1 among GTMAC and the CS-DCA.
7) above-mentioned reactant liquor is taken out, and its pH value is adjusted to neutrality with NaOH solution, centrifugal.Place bag filter in a large amount of clear water dialysis 3-5 days supernatant,, obtain white cotton shape product G-CS-DCA at last with the dialysis solution lyophilization.
8) get a certain amount of synthetic product G-CS-DCA, join in the PBS solution of pH=5.0-7.8, make the concentration of G-CS-DCA at 0.5-5mg/mL; In the extremely dissolving of 18-40 ℃ of following low-speed oscillation; Use sonde-type Ultrasound Instrument ultrasonic 1-3min in ice-water bath subsequently, 5-3s during work stops 1-3s; Repeat 2-4 time, can prepare the equally distributed nanoparticles solution of certain grain size.
9) getting a certain amount of G-CS-DCA is dissolved in the water; The concentration of G-CS-DCA is 2mg/mL; Under the 500-1500rpm stirring condition and to wherein dripping a certain amount of paclitaxel (PTX) methanol solution, make that the volume of methanol solution and the volume ratio of G-CS-DCA solution are 1: 5-1: 20, subsequently with it with the ultrasonic 10-40min of sonde-type Ultrasound Instrument; 5-3s during work stops 1-3s; The quality of paclitaxel and material G-CS-DCA be 0.10: 1 complete 0.3: 1;
10) place bag filter in a large amount of clear water dialysis 24 hours above-mentioned solution, use 0.8 μ m membrane filtration subsequently, and the cool-drying of will filtrating promptly obtains being loaded with the nano-medicament carrier material of PTX.
Production concentration is 1-4mg/mL in the said step 8), and ultransonic power is 40-100W.
The present invention has following advantage:
1. equipment is simple, easy operating.The present invention adopts sophisticated amide synthetic method (under catalyst EDC and NHS effect); Carry out classical electrophilic addition with primary amine in oxirane functional group and the glucosamine in the (+)-2,3-Epoxy-1-propanol and utilize amphiphilic chitosan derivative; Thereby through molecule self assembly principle, preparation nano-particle and medicine carrying thereof under ultrasonic and dialysis condition.Employed plant equipment has only a sonde-type Ultrasound Instrument, and operating procedure is simple.
2. controllable output can realize scale.The present invention adopt amide synthetic with oxirane functional group and glucosamine in primary amine carry out the high molecular controllable output of electrophilic addition technology preparation amphipathic chitose, and be easy to amplify, be suitable for lipophilic medicament, the loading of polypeptide transports.
3. nano-particle is easy to permeates cell membranes.The present invention adopts the particle diameter of the ultrasonic nano-micelle of preparing to be evenly distributed between the 150-300nm.Critical micelle concentration is 2 * 10
-2Mg/mL～5 * 10
-2Between the mg/mL, and surperficial positively charged, be easy to penetrate electronegative cell membrane.
4. nano-particle loads drug loading and medicine carrying efficient difference 15.2%-18.4% and the 91.5%-82.8% of antitumor drug PTX, and the nano-particle of its medicine carrying possesses the characteristic of slow release under external physiological condition.
In a word, the inventive method has that equipment is simple, easy to operate, nano particle diameter distribution homogeneous, and drug loading is big, and drug release is slow, can carry out the advantage of certain scale production.
Description of drawings
Fig. 1 chitosan and grafting deoxidation bile acid thereof form the infrared spectrum of product; Fig. 1-a is the FTIR of 24kDa chitosan raw material.Fig. 1-b is that the deoxidation bile acid is the FTIR of 0.10: 1 o'clock product with amino of chitosan glucose residue ratio.Fig. 1-c is that the deoxidation bile acid is the FTIR of 0.20: 1 o'clock product with amino of chitosan glucose residue ratio.Fig. 1-d is that the deoxidation bile acid is the FTIR of 0.30: 1 o'clock product with amino of chitosan glucose residue ratio.The amide I at 1652cm-1 place shows that with respect to the enhancing of 1600cm-1 place amido the percent grafting of deoxidation bile acid is to increase along with the increase of deoxidation bile acid in reacting with respect to the ratio of amino of chitosan glucose residue amount among Fig. 1.
Fig. 2 chitosan and derivant infrared spectrum thereof; Fig. 2-a is the FTIR of 24kDa chitosan raw material.Fig. 2-b is that deoxidation bile acid polysaccharide glucosamine residue ratio is the FTIR of 0.20: 1 o'clock product.Fig. 2-c be (+)-2,3-Epoxy-1-propanol with CCS-DCA in glucosamine residue ratio be the FTIR of 4: 1 o'clock products.
Fig. 3 is 0.20: 1 for the rate of charge of glucosamine among the deoxidation bile of the present invention preparation and the CS; And among (+)-2,3-Epoxy-1-propanol and the CCS-DCA rate of charge of glucosamine be the nano particle diameter scattergram that in pH=7.4PBS, prepares of 4: 1 o'clock product (Z-average=201.0 ± 3.0nm, PDI=0.151) and pattern phenogram (TEM).
The release profiles of Fig. 4 chitin medicine carrier paclitaxel loaded; Fig. 4-a was respectively 0.1: 1 for the rate of charge of glucosamine among the deoxidation bile for preparing for the present invention of the present invention preparation and the CS, and among (+)-2,3-Epoxy-1-propanol and the CS-DCA rate of charge of glucosamine be 4: 1 o'clock product the mass ratio of PTX be under 1: 0.225 condition behind the medicine carrying in pH=7.4PBS release profiles.Fig. 4-b is 0.2: 1 for the rate of charge of glucosamine among the deoxidation bile for preparing for the present invention of the present invention preparation and the CS, and among (+)-2,3-Epoxy-1-propanol and the CS-DCA rate of charge of glucosamine be 4: 1 o'clock product the mass ratio of PTX be under 1: 0.225 condition behind the medicine carrying in pH=7.4PBS release profiles.Fig. 4-c is 0.3: 1 for the rate of charge of glucosamine among the deoxidation bile for preparing for the present invention of the present invention preparation and the CS, and among (+)-2,3-Epoxy-1-propanol and the CS-DCA rate of charge of glucosamine be 4: 1 o'clock product the mass ratio of PTX be under 1: 0.225 condition behind the medicine carrying in pH=7.4PBS release profiles.
Fig. 5 was respectively 0.3: 1 for the rate of charge of glucosamine among the deoxidation bile for preparing for the present invention of the present invention preparation and the CS, and among (+)-2,3-Epoxy-1-propanol and the CS-DCA rate of charge of glucosamine be 4: 1 o'clock product the mass ratio of PTX be under 1: 0.225 condition behind the medicine carrying in pH=7.4 and pH=6.0PBS release profiles.
The specific embodiment
Embodiment 1
1) under the room temperature, 4g chitosan (24KDa) is dissolved in the 200mL aqueous hydrochloric acid solution, with the NaOH of 1N the pH of solution is adjusted to 5.6 subsequently, form the chitosan solution of transparent 2% (w/v).
2) get a certain amount of deoxidation bile acid; The ratio of the amount of glucosamine residue is 0.1: 1 in the amount that makes the deoxidation bile acid and the chitosan; It is joined in the DMSO solution of 100mL; The EDC and the NHS that amount such as in deoxidation bile acid solution, add subsequently, and keep EDC constant in 1.2: 1 with the ratio of the amount of deoxidation bile acid.Deoxidation bile acid, EDC and NHS are at room temperature in 1000rpm reaction 30min.
3) mixed solution that lithocholic acid, EDC and NHS is reacted 30min in the DMSO of 100mL slowly is added drop-wise in 30min in the chitosan solution of 2% (w/v), under the mixing speed of 1000rpm, reacts 24h.
4) above-mentioned 300mL reaction mixture is joined in the 200mL methanol, and with a certain amount of NaOH solution pH value is adjusted to neutrality and makes chitosan graft product deposition.Centrifugal collecting precipitation subsequently.
5) above-mentioned deposition is dissolved in the aqueous solution of 100mL acidity (pH1-4) again, and in the repetitive operation step 4) 3 times, but for the last time methanol being changed to ethanol gets final product.Thereby the white gels product vacuum drying under room temperature that obtains is prepared CS-DCA, and the FTIR of the product that this condition obtains sees Fig. 1 b.
6) above-mentioned product C S-DCA is got that 1g joins in the 50mL aqueous solution (0.5mL acetic acid) and be stirred to fully in 1000rpm and be mixed; Subsequently above-mentioned mixed liquor is heated to 50 ℃; And to wherein dripping a certain amount of (+)-2,3-Epoxy-1-propanol (Glycidol); Make that the rate of charge of the amount of substance of glucosamine is 4: 1 among (+)-2,3-Epoxy-1-propanol and the CS-DCA, reaction 24h.
7) above-mentioned reactant liquor is taken out, and its pH value is adjusted to neutrality with a certain amount of NaOH solution, centrifugal.Place bag filter in a large amount of clear water dialysis 3 days supernatant,, obtain white cotton shape product G-CS-DCA at last with the dialysis solution lyophilization.
8) get 10mg synthetic product G-CS-DCA, join 5mL, in the PBS of pH=7.4 (0.02M) solution; In the extremely dissolving of 37 ℃ of following low-speed oscillations; Use sonde-type Ultrasound Instrument ultrasonic in ice-water bath (80W) 2min subsequently, 5s during work stops 1s; Triplicate can prepare the equally distributed nanoparticles solution of certain grain size.It is 166.9nm that Nano ZS90 measures its particle diameter, and current potential is 0.4mV, and its critical aggregate concentration is 0.043mg/mL.
9) G-CS-DCA that gets a 20mg is dissolved in the 10mL water; Under the 1000rpm stirring condition and to wherein dripping a certain amount of lipophile micromolecule; Like antitumor activity medicine 4.5mg paclitaxel (PTX) methanol solution, make that the volume of methanol solution and the volume ratio of G-CS-DCA solution are 1: 10, subsequently with it with the ultrasonic 30min of sonde-type Ultrasound Instrument; 5s during work stops 1s.
10) place bag filter in a large amount of clear water dialysis 24 hours above-mentioned solution, filter with 0.8 μ m subsequently, and the cool-drying of will filtrating promptly obtains being loaded with the nano-medicament carrier material of PTX.The drug loading of the material that obtains under this condition and medicine carrying efficient are respectively 12.1% and 55.4%.
The medicament-carried nano granule for preparing under this condition release profiles under the condition of pH=7.4 is seen Fig. 4 a.
The mol ratio of glucosamine residue is 0.2: 1 in deoxidation acid and chitosan, and other condition is with specific embodiment 1.
The FTIR of the synthetic product of first step grafting deoxidation bile acid sign collection of illustrative plates is seen Fig. 1-c under this condition.
The FTIR sign collection of illustrative plates of the synthetic product of second step grafting dehydration glyceryl trimethyl ammonium chloride is seen Fig. 2-c under this condition.
The particle diameter intensity distribution of the nano-particle for preparing under this condition and TEM pattern phenogram see Fig. 3 (Z-average=201.0 ± 3.0nm, PDI=0.151).
The material for preparing under this condition carries the drug loading and the medicine carrying efficient of getting PTX and is respectively 17.3% and 88%.
The medicament-carried nano granule for preparing under this condition release profiles under the condition of pH=7.4 is seen Fig. 4 b.
Embodiment 3
The mol ratio of glucosamine residue is 0.3: 1 in deoxidation bile acid and chitosan, and other condition is with specific embodiment 1.
The FTIR of the synthetic product of first step grafting deoxidation bile acid sign collection of illustrative plates is seen Fig. 1-d under this condition.
The material for preparing under this condition carries the drug loading and the medicine carrying efficient of getting PTX and is respectively 18.3% and 91.5%.
The medicament-carried nano granule for preparing under this condition release profiles under the condition of pH=6.0 and pH=7.4 is seen Fig. 5.
Claims (6)
1. not charged amphiphilic chitosan nanometer pharmaceutical carrier is characterized in that:
Its successively by deoxidation bile acid and (+)-2,3-Epoxy-1-propanol respectively with chitosan in glucosamine carry out amidation process and thereby electrophilic addition reaction prepares the amphipathic uncharged block chitosan derivatives of good water solubility by N-[(2,3)-dihydroxypropyl] glucosamine unit, deoxidation bile acid amides glucosamine unit, acetylglucosamine unit and glucosamine unit composition.
2. said preparation of drug carriers method of claim 1; It is characterized in that: under the catalytic action of catalyst EDC and NHS; Hydrophilic macromolecule chitosan (Mw15KDa-100KDa) and lipophile micromolecule deoxidation bile acid with good biocompatibility pass through amidation process, thereby form good biocompatibility, degradable amphiphilic chitosan derivative CS-DCA; Through on the basis of CS-DCA, carrying out a step, form quaternary amine shape amphiphilic chitosan derivative through electrophilic reaction grafting quaternary amine shape micromolecule (+)-2,3-Epoxy-1-propanol (Glycidol); In wide pH value solution, utilize the principle of molecule self assembly, the nano-micelle that under ultrasound condition, prepares particle diameter 150-350nm and be evenly distributed; Because this micelle is special to be surface hydrophilic, inner oleophylic, can realize that therefore the embedding of lipophilic medicament such as paclitaxel is loaded, form the Nano medication delivery system.
3. according to the described method for preparing of claim 2, it is characterized in that: specific operation process is following,
1) under the room temperature, the 1-4g chitosan is dissolved in the 50-200mL aqueous hydrochloric acid solution, the NaOH with 1-10N adjusts to 5.0-6.0 with pH value of solution subsequently, forms the chitosan solution of transparent 1-2% (w/v);
2) get a certain amount of deoxidation bile acid; The ratio of the amount of glucosamine residue is 0.10-0.30 in the amount that makes the deoxidation bile acid and the chitosan; It is joined in the DMSO solution of 50-100mL; The EDC and the NHS that amount such as in deoxidation bile acid solution, add subsequently, and keep EDC constant in 1.0 with the ratio of the amount of deoxidation bile acid: 1-1.5: 1; Deoxidation bile acid, EDC and NHS are at room temperature in 500-1500rpm reaction 30-60min;
3) mixed solution that deoxidation bile acid, EDC and NHS is reacted 30-60min in DMSO slowly is added drop-wise in 30-60min in the chitosan solution, under the mixing speed of 500-1500rpm, reacts 18-36h;
4) above-mentioned reaction mixture is joined in the 200-500mL methanol, and with NaOH solution pH value is adjusted to neutrality and makes chitosan graft product deposition.Centrifugal collecting precipitation subsequently;
5) above-mentioned deposition is dissolved in the tart aqueous solution of 50-200mL pH1-5 again, and in the repetitive operation step 4) 3-5 time, but for the last time methanol being changed to ethanol gets final product; Thereby the white gels product vacuum drying under room temperature that obtains is prepared CS-DCA;
6) above-mentioned product C S-DCA is got that 0.5-4g joins in the 25-200mL aqueous solution (0.25-2.0mL acetic acid) and be stirred to fully in 500-1500rpm and be mixed; Subsequently above-mentioned mixed liquor is heated to 40-60 ℃; And to wherein dripping a certain amount of (+)-2,3-Epoxy-1-propanol (Glycidol), reaction 18-36h; And the amount of substance ratio of glucosamine is controlled to be 3: 1 to 6: 1 among GTMAC and the CS-DCA;
7) above-mentioned reactant liquor is taken out, and its pH value is adjusted to neutrality with NaOH solution, centrifugal; Place bag filter in a large amount of clear water dialysis 3-5 days supernatant,, obtain white cotton shape product G-CS-DCA at last with the dialysis solution lyophilization.
4. according to the described method for preparing of claim 3, it is characterized in that: the said white cotton shape product G-CS-DCA that obtains can further prepare the equally distributed nanoparticles solution of certain grain size,
Be specially: get synthetic product G-CS-DCA, join in the PBS solution of pH=5.0-7.8, make the concentration of G-CS-DCA at 0.5-5mg/mL; In the extremely dissolving of 18-40 ℃ of following low-speed oscillation; Use sonde-type Ultrasound Instrument ultrasonic 1-3min in ice-water bath subsequently, 5-3s during work stops 1-3s; Repeat 2-4 time, can prepare the equally distributed nanoparticles solution of certain grain size.
5. according to the described method for preparing of claim 4, it is characterized in that: said production concentration is 1-4mg/mL, and ultransonic power is 40-100W.
6. the application of the said pharmaceutical carrier of claim 1 is characterized in that:
1) getting a certain amount of G-CS-DCA is dissolved in the water; The concentration of G-CS-DCA is 2mg/mL; Under the 500-1500rpm stirring condition and to wherein dripping a certain amount of paclitaxel (PTX) methanol solution, make that the volume of methanol solution and the volume ratio of G-CS-DCA solution are 1: 5-1: 20, subsequently with it with the ultrasonic 10-40min of sonde-type Ultrasound Instrument; 5-3s during work stops 1-3s; The mass ratio of paclitaxel and material G-CS-DCA is 0.10: 1 to 0.3: 1;
2) place bag filter in a large amount of clear water dialysis 24 hours above-mentioned solution, use 0.8 μ m membrane filtration subsequently, and the cool-drying of will filtrating promptly obtains being loaded with the nano-medicament carrier material of PTX.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010213696 CN102309761A (en) | 2010-06-30 | 2010-06-30 | Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010213696 CN102309761A (en) | 2010-06-30 | 2010-06-30 | Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102309761A true CN102309761A (en) | 2012-01-11 |
Family
ID=45423569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010213696 Pending CN102309761A (en) | 2010-06-30 | 2010-06-30 | Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309761A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102775515A (en) * | 2012-06-12 | 2012-11-14 | 中国科学院化学研究所 | Amphiphilic chitosan derivatives, and preparation method and application thereof |
| CN112438988A (en) * | 2020-11-23 | 2021-03-05 | 烟台大学 | Charge reversal type core/shell drug carrier based on self-assembly, preparation method and application thereof |
| CN114569781A (en) * | 2022-03-02 | 2022-06-03 | 上海交通大学 | Polysaccharide conjugate hemostatic material, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711873A (en) * | 2008-10-06 | 2010-05-26 | 中国科学院大连化学物理研究所 | Method for preparing amphiphilic chitosan nanometer medicament carrier |
-
2010
- 2010-06-30 CN CN 201010213696 patent/CN102309761A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711873A (en) * | 2008-10-06 | 2010-05-26 | 中国科学院大连化学物理研究所 | Method for preparing amphiphilic chitosan nanometer medicament carrier |
Non-Patent Citations (1)
| Title |
|---|
| 《中国化学会第27届学术年会第13分会场摘要集》 20100620 刘袖洞等 "两亲壳聚糖纳米载体的制备与药物释放" 第13页 1 , * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102775515A (en) * | 2012-06-12 | 2012-11-14 | 中国科学院化学研究所 | Amphiphilic chitosan derivatives, and preparation method and application thereof |
| CN112438988A (en) * | 2020-11-23 | 2021-03-05 | 烟台大学 | Charge reversal type core/shell drug carrier based on self-assembly, preparation method and application thereof |
| CN112438988B (en) * | 2020-11-23 | 2021-12-07 | 烟台大学 | Charge reversal type core/shell drug carrier based on self-assembly, preparation method and application thereof |
| CN114569781A (en) * | 2022-03-02 | 2022-06-03 | 上海交通大学 | Polysaccharide conjugate hemostatic material, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102309760A (en) | Cationic amphiphilic chitosan nano drug carrier and preparation method and application thereof | |
| Raza et al. | Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile | |
| CN101711873B (en) | Method for preparing amphiphilic chitosan nanometer medicament carrier | |
| CN110801431B (en) | Construction and application of core-shell type intelligent nano delivery system | |
| CN104530256B (en) | Hyaluronic acid-vitamin E succinate polymer as well as preparation and application thereof | |
| CN106265510A (en) | Multistage target polymer micelle of pH trigger-type release and preparation method thereof in a kind of tumor cell | |
| CN104436203A (en) | Preparation method and application of hyaluronic acid modified by vitamin E succinate | |
| CN103611165A (en) | Hyaluronic acid- cyclodextrin-adamantane polyethylene glycol carrier as well as preparation method and application thereof | |
| CN111423591B (en) | Amphiphilic graft copolymer based on hyaluronic acid and preparation method and application thereof | |
| CN101665569B (en) | Hydrophilic polymer the side chain of which is modified by lipoic acid and preparation and application thereof | |
| CN111870579B (en) | Tumor-targeted nano micelle, preparation method and application of nano micelle as drug carrier | |
| KR20080043638A (en) | Low molecular water soluble chitosan nanoparticles for delivery of gene carrier modified with folate as a target ligand and preparation method thereof | |
| CN107137716A (en) | A kind of polyethylene glycol conjugation circular polypeptides iRGD and diosgenin medicine-carried nano particles preparation | |
| CN102212146B (en) | Thioctic acid-modified hydrophilic polymer for side chain | |
| CN101780281B (en) | Application of N-arginine chitosan as percutaneous sorbefacient | |
| Gao et al. | Hyaluronan-based multifunctional nano-carriers for combination cancer therapy | |
| CN104892917B (en) | Glucosamine-modified polyethyleneglycol-polylactic acid, preparation method therefor and application thereof | |
| CN103976976B (en) | A kind of bag carries the method for making of human growth hormone recombinant's small capsule of slow-soluble medicine | |
| Zhang et al. | Polysaccharide based supramolecular injectable hydrogels for in situ treatment of bladder cancer | |
| CN109705236B (en) | Hyaluronic acid derivative and preparation method and application thereof | |
| CN101721710A (en) | Cholesteryl-carboxymethyl Curdlan nanometer particle and preparing method | |
| CN102309761A (en) | Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof | |
| CN108395543B (en) | Modified polyrotaxane, medicine-carrying micelle based on polyrotaxane and preparation method and application of medicine-carrying micelle | |
| CN104434792A (en) | Polymer micelle, preparation method thereof, antitumor pharmaceutical composition, preparation and preparation method thereof | |
| Mu et al. | Progress in chitin/chitosan and their derivatives for biomedical applications: Where we stand |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120111 |